Amifampridine-d3

Amifampridine-d3 (3,4-Diaminopyridine-d3) is deuterium labeled Amifampridine. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB) . Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs) . Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research[1][2][3].

Product Specifications

CAS Number

[2732980-95-7]

Product Name Alternative

3,4-Diaminopyridine-d3

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Potassium Channel

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

NC1=C(C([2H])=C([2H])N=C1[2H])N

Molecular Formula

C5H4D3N3

Molecular Weight

112.15

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Maarten J Titulaer, et al. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011 Dec;10 (12) :1098-107.|[3]Ojala KS, et al. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021 Jan-Jun;296:100302.|[4]T L Harris, et al. Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. Chem Commun (Camb) . 2016 Mar 18;52 (22) :4187-90.